Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.
CONCLUSIONS: The following 2 hypothetical proposals should be proven by large-scale clinical trials. Immunohistochemical recognition of apocrine-type triple-negative breast cancer with low Ki-67 labeling is important for avoiding ineffective/unnecessary neoadjuvant chemotherapy. By employing appropriate clinical imaging, period-shortening is achievable in basal-like triple-negative breast cancer with high Ki-67 labeling.
PMID: 32677589 [PubMed - in process]
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Kubouchi K, Shimada K, Yokoe T, Tsutsumi Y Tags: Technol Cancer Res Treat Source Type: research
More News: Adenoids | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | MRI Scan | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy